"In the second quarter, we continued to make meaningful progress with our two key programs,” said Ofer Gonen, Chief Executive Officer of MediWound. "The EscharEx Phase III VALUE trial is advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results